Pelikan bags $69m for diabetes monitoring technology:
This article was originally published in Clinica
Palo Alto, California-based Pelikan Technologies is to take its Pelikan Sun electronic lancing device to the US after raising $89m through a series F equity financing and a venture loan facility. The series F round, which raised $69m, was led by Clarus Ventures. The $20m debt financing was provided by General Electric Capital and Oxford Finance. The Pelikan Sun has been approved by the FDA and was recently launched in Australia and Europe. Its US debut is slated for the first quarter of 2008. Pelikan Technologies said it will also use the new capital to complete development of its next-generation, fully-integrated blood glucose system and finance the launch of the product, which is also expected next year.
You may also be interested in...
ResMed plans to double or even triple production of intensive ventilators and sleep apnea machines this year amid rising demand by hospitals to use CPAP and BPAP machines to treat COVID-19 patients during the ventilator shortage.
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.